ArticleFrontiers in pharmacology2026
Pharmacological pitfalls in inpatient lung transplant care and management of medication risks.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacotherapy after lung transplantation is complex and prone to drug-drug interactions, dosing errors, and toxicity. We retrospectively analysed 259 comments from weekly interdisciplinary rounds at the University Hospital Zurich between September 2022 and April 2024 to identify common pharmacological pitfalls in inpatient lung transplant recipients. The cohort included 62 patients (mean age 56.1 years; 40.3% female). Most comments concerned potential risks rather than confirmed harm: 54.4% were classified as potential side effects and 21.6% as potential loss of effectiveness. Interactions were the most frequent subcategory (45.6%), followed by dosage problems (14.3%). Tacrolimus was the most commonly commented on drug, often due to interactions with metamizole/dipyrone, resulting in fluctuating tacrolimus levels. Other frequent issues included QTc-prolonging combinations (e.g., domperidone with escitalopram or amiodarone in addition to itraconazole) and reduced levothyroxine absorption due to divalent cations. Only five comments reflected actual adverse outcomes, indicating overall high drug safety. These findings are consistent with the literature describing the importance of systematic pharmacological review and interdisciplinary collaboration to improve medication safety and standardise care in lung transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.